CPHI Celebration awards recognises exceptional enterprises across eight comprehensive categories spanning the entire pharmaceutical industry chain, fully showcasing the outstanding achievements in the pharma industry.  Winning enterprises are invited to attend the exclusive CPHI Celebration awards & Networking party on the evening of 16 June 2026. Apply now and join us for a prestigious evening of networking, connecting and celebrating where pharmaceutical excelle

insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS. BMS has nominated two additional targets, ALS-2 and ALS-3, which were iden

SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas. The U.S. Food and Drug Administration (FDA) carried out a general inspection of the site from February 9 to February 12, 2026. After a thorough review of the facility’s quality systems and manufacturing operations, the FDA completed the inspection without issuing a Form 483. This “No Action Indicated” (NAI) status confir

Researchers from Southern Cross University (SCU), in partnership with the Melbourne Integrative Oncology Group (MIOG), are launching an Australian-first clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment for high-grade glioma brain cancer. Backed by a $1 million gift from an anonymous donor, the collaborative research will examine whether delivering oxygen in a pressurised environment during active cancer treatment

GenScript announced the official opening of its first European mRNA production site in Delft, the Netherlands, marking a significant expansion of the company's global mRNA platform and reinforcing Europe as a core pillar of its integrated R&D and production network. The Delft facility strengthens GenScript's transatlantic biotechnology infrastructure, enabling greater regional proximity, regulatory alignment, and supply chain resilience for European innovators developing

Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-

Locus Cell Co., Ltd. ("Locus Cell"), a Taiwan-based cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO), and Charles River Laboratories ("Charles River"), a global contract research organization (CRO) providing drug development support and biologics testing solutions, have signed a Memorandum of Understanding (MoU) during the APAC Biomanufacturing Leadership Summit 2026 in Singapore. The Summit, positioned as the flagship APAC b

Everest Medicines a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY®(etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. As a once-daily oral therapy with sustained efficacy, a favorable saf

Beijing Tsingke Biotech Co., Ltd. ("Tsingke Biotech") and iGeneTech Bioscience Co., Ltd. ("iGeneTech") have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together the strengths of both companies to drive innovation, streamline product development, and expand market reach. Harnessing Expertise to Transform the Industry Synthetic biology is rapidly emerging as a transformati

FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will be presented this week at the Festival of Biologics conference in San Diego. To streamline purification processes, FUJIFILM Biotechnologies, in collaboration with the University of Edinburgh, deve